An investment from the nonprofit Beyond Celiac provides more than capital; it offers powerful third-party validation for a novel therapeutic target. For investors and potential pharma partners, this endorsement from a patient organization helps de-risk a new technology and demonstrates a clear patient need and interest.

After Actuate Therapeutics released positive early trial data for pediatric cancers, leading international research groups initiated contact. They not only wanted to help develop the drug but had already independently tested the molecule, demonstrating how powerful data can attract inbound, high-caliber partnership opportunities.

Many firms view patient engagement as a compliance task that adds cost. However, data shows integrating patient experience into development from the start speeds up clinical trial recruitment and execution, reduces FDA amendments, and accelerates time-to-market, providing clear ROI.

The Biotech CEO Sisterhood operates on a counterintuitive principle: eliminate competition among members. The goal is to collectively maximize company success and patient impact by freely sharing resources, advice, and lessons learned—even on sensitive topics like gracefully shutting down a company.

A common failure in biotech is viewing patients solely as data sources rather than as human partners in the development process. This perspective leads to unnecessarily complex protocols with high patient burden. The most successful firms build relationships with patient advocacy groups and design trials that respect the patient's experience.

For years, Actuate's CEO has shared progress with large pharma companies, not just for early deal-making, but to get critical feedback on their development plan. This helps them understand what data potential acquirers need to see to make a compelling offer later.

In the rare disease space, success hinges on deep patient community engagement. Smaller, nimbler biotechs often excel at creating these essential personal ties, giving them a significant advantage over larger pharmaceutical companies.

To demonstrate its drug could overcome resistance, Actuate designed a trial where patients who had already failed a specific chemotherapy were given the exact same regimen again, but this time with Actuate's drug added. The resulting increased efficacy across eight different cancers provided powerful, direct proof of the drug's mechanism.

A crucial piece of advice for biotech founders is to interact with patients as early as possible. This 'patient first' approach helps uncover unmet needs in their treatment journey, providing a more powerful and differentiated perspective than focusing solely on the scientific or commercial landscape.